SCHEMBL4272189

SCHEMBL4272189

Cc1ccc(C(=O)Oc2ccc(Cl)c(-c3cc(C)c4nc(Nc5ccc(OCCN6CCCC6)cc5)nnc4c3)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 16/20 1.00
ABL1 P00519 8/20 0.89
YES1 P07947 6/20 0.89
EPHB4 P54760 6/20 0.89
PDGFRB P09619 5/20 0.89
LCK P06239 4/20 0.89
RET P07949 3/20 0.89
GAK O14976 2/20 0.89
RIPK2 O43353 2/20 0.89
BCR P11274 2/20 0.89
EPHA2 P29317 2/20 0.89
EPHB2 P29323 2/20 0.89
ABL2 P42684 2/20 0.89
EPHA4 P54764 2/20 0.89
DDR1 Q08345 2/20 0.89
TGFBR2 P37173 1/20 0.89
ACVR2B Q13705 1/20 0.89
KDR P35968 5/20 0.75
CIT O14578 1/20 0.75
EPHB6 O15197 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tg100-801 SCHEMBL29941250 0.94 YES1 (1.00) SRCABL1YES1EPHB4PDGFRB
Tg100-801 SCHEMBL12198196 0.94 YES1 (1.00) SRCABL1YES1EPHB4PDGFRB
Tg100-801 SCHEMBL29363355 0.94 YES1 (0.99) SRCABL1YES1EPHB4PDGFRB
SCHEMBL4272203 0.91 SRC (1.00) SRCABL1YES1EPHB4PDGFRB
SCHEMBL12198198 0.90 ABL1 (0.87) SRCABL1YES1EPHB4PDGFRB
SCHEMBL12198199 0.89 SRC (0.86) SRCABL1YES1EPHB4PDGFRB
SCHEMBL15095269 0.89 SRC (0.86) SRCABL1YES1EPHB4PDGFRB
SCHEMBL4268136 0.89 SRC (1.00) SRCABL1YES1EPHB4PDGFRB
SCHEMBL4264210 0.89 SRC (0.85) SRCABL1YES1EPHB4PDGFRB
SCHEMBL4265021 0.87 SRC (1.00) SRCABL1YES1EPHB4PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 EP disclosed
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 EP disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 EP disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 EP disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS TARGEGEN INC. 2011-10-06 US disclosed
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS TARGEGEN INC. 2011-10-06 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-20050245524-A1 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES SRC, CAMK4, CAMK2G SRC 1/4885ABL1 15/4885YES1 237/4885
US-20090275569-A1 Benzotriazine Inhibitors of Kinases SRC, CAMK4, CAMK2G SRC 1/4885ABL1 15/4885YES1 237/4885
US-20050245524-A1 Benzotriazine inhibitors of kinases SRC, CAMK4, CAMK2G SRC 1/4885ABL1 15/4885YES1 237/4885
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS AQP3, AQP1, AQP4 SRC 4062/4885ABL1 4620/4885YES1 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.